1
|
Segedin B, Kobav M, Zobec Logar HB. The Use of 3D Printing Technology in Gynaecological Brachytherapy-A Narrative Review. Cancers (Basel) 2023; 15:4165. [PMID: 37627193 PMCID: PMC10452889 DOI: 10.3390/cancers15164165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2023] [Revised: 08/13/2023] [Accepted: 08/15/2023] [Indexed: 08/27/2023] Open
Abstract
Radiation therapy, including image-guided adaptive brachytherapy based on magnetic resonance imaging, is the standard of care in locally advanced cervical and vaginal cancer and part of the treatment in other primary and recurrent gynaecological tumours. Tumour control probability increases with dose and brachytherapy is the optimal technique to increase the dose to the target volume while maintaining dose constraints to organs at risk. The use of interstitial needles is now one of the quality indicators for cervical cancer brachytherapy and needles should optimally be used in ≥60% of patients. Commercially available applicators sometimes cannot be used because of anatomical barriers or do not allow adequate target volume coverage due to tumour size or topography. Over the last five to ten years, 3D printing has been increasingly used for manufacturing of customised applicators in brachytherapy, with gynaecological tumours being the most common indication. We present the rationale, techniques and current clinical evidence for the use of 3D-printed applicators in gynaecological brachytherapy.
Collapse
Affiliation(s)
- Barbara Segedin
- Department of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia; (M.K.); (H.B.Z.L.)
- Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - Manja Kobav
- Department of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia; (M.K.); (H.B.Z.L.)
| | - Helena Barbara Zobec Logar
- Department of Radiation Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia; (M.K.); (H.B.Z.L.)
- Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
| |
Collapse
|
2
|
Fahimian BP, Liu W, Skinner L, Yu AS, Phillips T, Steers JM, DeMarco J, Fraass BA, Kamrava M. 3D printing in brachytherapy: A systematic review of gynecological applications. Brachytherapy 2023; 22:446-460. [PMID: 37024350 DOI: 10.1016/j.brachy.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 12/27/2022] [Accepted: 02/02/2023] [Indexed: 04/08/2023]
Abstract
PURPOSE To provide a systematic review of the applications of 3D printing in gynecological brachytherapy. METHODS Peer-reviewed articles relating to additive manufacturing (3D printing) from the 34 million plus biomedical citations in National Center for Biotechnology Information (NCBI/PubMed), and 53 million records in Web of Science (Clarivate) were queried for 3D printing applications. The results were narrowed sequentially to, (1) all literature in 3D printing with final publications prior to July 2022 (in English, and excluding books, proceedings, and reviews), and then to applications in, (2) radiotherapy, (3) brachytherapy, (4) gynecological brachytherapy. Brachytherapy applications were reviewed and grouped by disease site, with gynecological applications additionally grouped by study type, methodology, delivery modality, and device type. RESULTS From 47,541 3D printing citations, 96 publications met the inclusion criteria for brachytherapy, with gynecological clinical applications compromising the highest percentage (32%), followed by skin and surface (19%), and head and neck (9%). The distribution of delivery modalities was 58% for HDR (Ir-192), 35% for LDR (I-125), and 7% for other modalities. In gynecological brachytherapy, studies included design of patient specific applicators and templates, novel applicator designs, applicator additions, quality assurance and dosimetry devices, anthropomorphic gynecological applicators, and in-human clinical trials. Plots of year-to-year growth demonstrate a rapid nonlinear trend since 2014 due to the improving accessibility of low-cost 3D printers. Based on these publications, considerations for clinical use are provided. CONCLUSIONS 3D printing has emerged as an important clinical technology enabling customized applicator and template designs, representing a major advancement in the methodology for implantation and delivery in gynecological brachytherapy.
Collapse
Affiliation(s)
- Benjamin P Fahimian
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.
| | - Wu Liu
- Department of Radiation Oncology, Stanford University, Stanford, CA
| | - Lawrie Skinner
- Department of Radiation Oncology, Stanford University, Stanford, CA
| | - Amy S Yu
- Department of Radiation Oncology, Stanford University, Stanford, CA
| | - Tiffany Phillips
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Jennifer M Steers
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
| | - John DeMarco
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Benedick A Fraass
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Mitchell Kamrava
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
| |
Collapse
|
3
|
Meftahi M, Fields E, Guy C, Song WY. The Design of a Novel Direction Modulated Brachytherapy Vaginal Cylinder Applicator for Optimizing Coverage of the Apex. Med Phys 2022; 49:3926-3935. [DOI: 10.1002/mp.15666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Revised: 03/03/2022] [Accepted: 01/28/2022] [Indexed: 11/09/2022] Open
Affiliation(s)
- Moeen Meftahi
- Department of Radiation Oncology Virginia Commonwealth University Richmond Virginia USA
| | - Emma Fields
- Department of Radiation Oncology Virginia Commonwealth University Richmond Virginia USA
| | - Christopher Guy
- Department of Radiation Oncology Virginia Commonwealth University Richmond Virginia USA
| | - William Y. Song
- Department of Radiation Oncology Virginia Commonwealth University Richmond Virginia USA
| |
Collapse
|
4
|
Vedelago J, Geser FA, Muñoz ID, Stabilini A, Yukihara EG, Jaekel O. Assessment of secondary neutrons in particle therapy by Monte Carlo simulations. Phys Med Biol 2021; 67. [PMID: 34905742 DOI: 10.1088/1361-6560/ac431b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 12/14/2021] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The purpose of this study is to estimate the energy and angular distribution of secondary neutrons inside a phantom in hadron therapy, which will support decisions on detector choice and experimental setup design for in-phantom secondary neutron measurements. APPROACH Dedicated Monte Carlo simulations were implemented, considering clinically relevant energies of protons, helium and carbon ions. Since scored quantities can vary from different radiation transport models, the codes FLUKA, TOPAS and MCNP were used. The geometry of an active scanning beam delivery system for heavy ion treatment was implemented, and simulations of pristine and spread-out Bragg peaks were carried out. Previous studies, focused on specific ion types or single energies, are qualitatively in agreement with the obtained results. MAIN RESULTS The secondary neutrons energy distributions present a continuous spectrum with two peaks, one centred on the thermal/epithermal region, and one on the high-energy region, with the most probable energy ranging from 19 MeV up to 240 MeV, depending on the ion type and its initial energy. The simulations show that the secondary neutron energies may exceed 400 MeV and, therefore, suitable neutron detectors for this energy range shall be needed. Additionally, the angular distribution of the low energy neutrons is quite isotropic, whereas the fast/relativistic neutrons are mainly scattered in the down-stream direction. SIGNIFICANCE It would be possible to minimize the influence of the heavy ions when measuring the neutron-generated recoil protons by selecting appropriate measurement positions within the phantom. Although there are discrepancies among the three Monte Carlo codes, the results agree qualitatively and in order of magnitude, being sufficient to support further investigations with the ultimate goal of mapping the secondary neutron doses both in- and out-of-field in hadrontherapy. The obtained secondary neutron spectra are available as supplementary material.
Collapse
Affiliation(s)
- José Vedelago
- German Cancer Research Centre, Im Neuenheimer Feld 280, Heidelberg, 69120, GERMANY
| | - Federico A Geser
- Paul Scherrer Institut, Forschungsstrasse 111, Villigen PSI, 5232, SWITZERLAND
| | - Iván D Muñoz
- German Cancer Research Centre, Im Neuenheimer Feld 280, Heidelberg, 69120, GERMANY
| | - Alberto Stabilini
- Paul Scherrer Institut, Forschungsstrasse 111, Villigen PSI, 5235, SWITZERLAND
| | - Eduardo G Yukihara
- Paul Scherrer Institut, Forschungsstrasse 111, Villigen PSI, 5232, SWITZERLAND
| | - Oliver Jaekel
- German Cancer Research Centre, Im Neuenheimer Feld 280, Heidelberg, 69120, GERMANY
| |
Collapse
|
5
|
Song WY, Robar JL, Morén B, Larsson T, Carlsson Tedgren Å, Jia X. Emerging technologies in brachytherapy. Phys Med Biol 2021; 66. [PMID: 34710856 DOI: 10.1088/1361-6560/ac344d] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 10/28/2021] [Indexed: 01/15/2023]
Abstract
Brachytherapy is a mature treatment modality. The literature is abundant in terms of review articles and comprehensive books on the latest established as well as evolving clinical practices. The intent of this article is to part ways and look beyond the current state-of-the-art and review emerging technologies that are noteworthy and perhaps may drive the future innovations in the field. There are plenty of candidate topics that deserve a deeper look, of course, but with practical limits in this communicative platform, we explore four topics that perhaps is worthwhile to review in detail at this time. First, intensity modulated brachytherapy (IMBT) is reviewed. The IMBT takes advantage ofanisotropicradiation profile generated through intelligent high-density shielding designs incorporated onto sources and applicators such to achieve high quality plans. Second, emerging applications of 3D printing (i.e. additive manufacturing) in brachytherapy are reviewed. With the advent of 3D printing, interest in this technology in brachytherapy has been immense and translation swift due to their potential to tailor applicators and treatments customizable to each individual patient. This is followed by, in third, innovations in treatment planning concerning catheter placement and dwell times where new modelling approaches, solution algorithms, and technological advances are reviewed. And, fourth and lastly, applications of a new machine learning technique, called deep learning, which has the potential to improve and automate all aspects of brachytherapy workflow, are reviewed. We do not expect that all ideas and innovations reviewed in this article will ultimately reach clinic but, nonetheless, this review provides a decent glimpse of what is to come. It would be exciting to monitor as IMBT, 3D printing, novel optimization algorithms, and deep learning technologies evolve over time and translate into pilot testing and sensibly phased clinical trials, and ultimately make a difference for cancer patients. Today's fancy is tomorrow's reality. The future is bright for brachytherapy.
Collapse
Affiliation(s)
- William Y Song
- Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - James L Robar
- Department of Radiation Oncology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Björn Morén
- Department of Mathematics, Linköping University, Linköping, Sweden
| | - Torbjörn Larsson
- Department of Mathematics, Linköping University, Linköping, Sweden
| | - Åsa Carlsson Tedgren
- Radiation Physics, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.,Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.,Department of Oncology Pathology, Karolinska Institute, Stockholm, Sweden
| | - Xun Jia
- Innovative Technology Of Radiotherapy Computations and Hardware (iTORCH) Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
| |
Collapse
|
6
|
Park H, Paganetti H, Schuemann J, Jia X, Min CH. Monte Carlo methods for device simulations in radiation therapy. Phys Med Biol 2021; 66:10.1088/1361-6560/ac1d1f. [PMID: 34384063 PMCID: PMC8996747 DOI: 10.1088/1361-6560/ac1d1f] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 08/12/2021] [Indexed: 11/12/2022]
Abstract
Monte Carlo (MC) simulations play an important role in radiotherapy, especially as a method to evaluate physical properties that are either impossible or difficult to measure. For example, MC simulations (MCSs) are used to aid in the design of radiotherapy devices or to understand their properties. The aim of this article is to review the MC method for device simulations in radiation therapy. After a brief history of the MC method and popular codes in medical physics, we review applications of the MC method to model treatment heads for neutral and charged particle radiation therapy as well as specific in-room devices for imaging and therapy purposes. We conclude by discussing the impact that MCSs had in this field and the role of MC in future device design.
Collapse
Affiliation(s)
- Hyojun Park
- Department of Radiation Convergence Engineering, Yonsei University, Wonju, Republic of Korea
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States of America
| | - Jan Schuemann
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States of America
| | - Xun Jia
- Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75235, United States of America
| | - Chul Hee Min
- Department of Radiation Convergence Engineering, Yonsei University, Wonju, Republic of Korea
| |
Collapse
|
7
|
Semeniuk O, Cherpak A, Robar J. Design and evaluation of 3D printable patient-specific applicators for gynecologic HDR brachytherapy. Med Phys 2021; 48:4053-4063. [PMID: 33880777 DOI: 10.1002/mp.14888] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/17/2021] [Accepted: 04/01/2021] [Indexed: 01/13/2023] Open
Abstract
PURPOSE The purpose of this study is to improve dose distribution and organ-at-risk sparing during gynecologic HDR brachytherapy with patient-specific applicators. The majority of applicators used today are generic in design and do not allow for dose modulation for patient-specific shaping of dose distributions. Their performance might be adjusted with commercially available wedge shields; however, this provides dose modulation in the orthogonal plane only and does not allow for variation along the length of the applicator. Generic applicators are available only in standard sizes and geometries, and provide suboptimal patient fit with limited dose modulation. METHODS In this paper we use Monte Carlo modeling for comprehensive characterization of radiologic properties of various 3D printable biocompatible and sterilizable materials with comparison to water. Based on these results, we choose the optimal set of materials for a patient-specific applicator. We develop a novel method to design the patient-specific applicator without incurring a significant increase in treatment time or changes to clinical workflow. Finally, using an example of two selected vaginal cancers, we compare the performance of patient-specific and water-equivalent applicators in terms of target coverage and rectum sparing. RESULTS In the energy range from 1 MeV to 4 MeV, all materials have similar attenuation coefficients. In the range from ~2 keV to 1 MeV and above 4 MeV, tungsten-polylactic acid composite (WPLA) was seen to have the highest attenuation coefficient. The dose distribution of the water-equivalent applicator was found to be symmetric about its central axis. At the same time patient-specific shielded applicators exhibit well-modulated dose distributions. Their isodose lines are seen to spread radially into the patient, while merging close to the applicator surface, where WPLA shielding has been applied. CONCLUSIONS The patient-specific cylinders provide comparable dose to the target, while offering advanced healthy tissue sparing, not achievable with the generic design.
Collapse
Affiliation(s)
- Oleksii Semeniuk
- Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, M5G 1X6, Canada
| | - Amanda Cherpak
- Medical Physics, Nova Scotia Health, Halifax, B3H 1V7, Canada.,Department of Radiation Oncology, Dalhousie University, Halifax, B3H 4R2, Canada.,Department of Physics & Atmospheric Science, Dalhousie University, Halifax, B3H 4R2, Canada
| | - James Robar
- Medical Physics, Nova Scotia Health, Halifax, B3H 1V7, Canada.,Department of Radiation Oncology, Dalhousie University, Halifax, B3H 4R2, Canada.,Department of Physics & Atmospheric Science, Dalhousie University, Halifax, B3H 4R2, Canada
| |
Collapse
|
8
|
Wu J, Xie Y, Ding Z, Li F, Wang L. Monte Carlo study of TG-43 dosimetry parameters of GammaMed Plus high dose rate 192 Ir brachytherapy source using TOPAS. J Appl Clin Med Phys 2021; 22:146-153. [PMID: 33955134 PMCID: PMC8200518 DOI: 10.1002/acm2.13252] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 01/06/2021] [Accepted: 03/28/2021] [Indexed: 12/29/2022] Open
Abstract
PURPOSE To develop a simulation model for GammaMed Plus high dose rate 192 Ir brachytherapy source in TOPAS Monte Carlo software and validate it by calculating the TG-43 dosimetry parameters and comparing them with published data. METHODS We built a model for GammaMed Plus high dose rate brachytherapy source in TOPAS. The TG-43 dosimetry parameters including air-kerma strength SK , dose-rate constant Λ, radial dose function gL (r), and 2D anisotropy function F(r,θ) were calculated using Monte Carlo simulation with Geant4 physics models and NNDC 192 Ir spectrum. Calculations using an old 192 Ir spectrum were also carried out to evaluate the impact of incident spectrum and cross sections. The results were compared with published data. RESULTS For calculations using the NNDC spectrum, the air-kerma strength per unit source activity SK /A and Λ were 1.0139 × 10-7 U/Bq and 1.1101 cGy.h-1 .U-1 , which were 3.56% higher and 0.62% lower than the reference values, respectively. The gL (r) agreed with reference values within 1% for radial distances from 2 mm to 20 cm. For radial distances of 1, 3, 5, and 10 cm, the agreements between F(r,θ) from this work and the reference data were within 1.5% for 15° < θ < 165°, and within 4% for all θ values. The discrepancies were attributed to the updated source spectrum and cross sections. They caused deviations of the SK /A of 2.90% and 0.64%, respectively. As for gL (r), they caused average deviations of -0.22% and 0.48%, respectively. Their impact on F(r,θ) was not quantified for the relatively high statistical uncertainties, but basically they did not result in significant discrepancies. CONCLUSION A model for GammaMed Plus high dose rate 192 Ir brachytherapy source was developed in TOPAS and validated following TG-43 protocols, which can be used for future studies. The impact of updated incident spectrum and cross sections on the dosimetry parameters was quantified.
Collapse
Affiliation(s)
- Jianan Wu
- Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.,Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
| | - Yaoqin Xie
- Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China
| | - Zhen Ding
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
| | - Feipeng Li
- Shenzhen Key Laboratory of Advanced Machine Learning and Application, College of Mathematics and Statistics, Shenzhen University, Shenzhen, 518060, China
| | - Luhua Wang
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.,Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| |
Collapse
|